Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer1

Glenn Liu, Yu Hui Chen, Jill Kolesar, Wei Huang, Robert DiPaola, Michael Pins, Michael A Carducci, Mark Stein, Glenn J. Bubley, George Wilding

Research output: Contribution to journalArticle


Purpose: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. Patients and methods: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT)

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Issue number2
Publication statusPublished - Feb 2013



  • Clinical trial
  • Epidermal growth factor receptor
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this